Fig. 1

A Study design used to describe associations among patient/tumor/treatment characteristics, baseline comorbidities, and prior non-cancer chronic medication use and patterns of adherence to adjuvant endocrine therapy (AET). B Hypothetical patient scenarios for measuring patterns of adjuvant endocrine therapy adherence (AET) in premenopausal breast cancer patients during five years of follow-up. Abbreviations TAM, tamoxifen; DBCG, Danish Breast Cancer Group; AET, adjuvant endocrine therapy; CCI, Charlson Comorbidity Index; PDC, proportion of days covered. ^aPatients censored at time of recurrence, death, second primary cancer, emigration, or five years after breast cancer diagnosis. ^bA maximum of 182 days (or 6-month) dosage was allowed to be carried forward to the next interval. ^cFigures developed using Schneeweiss et al. template diagrams [27].